Certified Clinical Research Associate (CCRA) Practice Exam 2026 – Complete Preparation Guide

The required timeline for reporting a serious unexpected adverse drug reaction (SUSAR) to regulatory authorities is 15 calendar days. This requirement is critical because it ensures timely communication of potential safety risks associated with drug treatment, which is essential for patient safety and regulatory compliance.

Regulatory agencies, such as the FDA in the United States or the European Medicines Agency (EMA) in Europe, mandate this reporting timeframe to facilitate prompt assessment and action, which may include changes to product labeling, warnings to healthcare professionals, or additional studies. Being able to quickly identify and address serious adverse events contributes to the overall safety monitoring of drugs on the market and helps to protect public health.

While other options such as 7, 30, and 60 calendar days exist within different contexts and regulations, they do not align with the specific requirement for SUSAR reporting, which is firmly established at 15 calendar days. Understanding this timeframe is critical for clinical research associates, as it reflects the importance of vigilance in pharmacovigilance activities.